Yahoo · Nov 16, 2026
Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration
SAN DIEGO, November 16, 2026--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced an expanded collaboration with Meiji Seika Pharma Co., Ltd. ("Meiji"), including a $50 million equity investment at an 80% premium. The expanded partnership includes a memorandum of understanding ("MOU") related to pandemic preparedness and response in Japan and an exclusive

